ESPR FY 2012 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$501M

FY 2012 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$10M

Net Income

-$12M

EPS (Diluted)

$-1.22

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$79,861

Balance Sheet

Total Assets

$7M

Total Liabilities

$25M

Stockholders' Equity

-$17M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$10M	-$10M	-0.4%
Net Income	-$12M	-$11M	-8.5%